Novo Nordisk’s lawsuit against Eli Lilly over ads highlights intense competition in GLP-1 market

The Danish company Novo Nordisk says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs.

Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.